天风证券给予欧林生物增持评级，破伤风疫苗持续放量，金葡菌疫苗即将进入收获期

Core Viewpoint - Tianfeng Securities has issued a report on August 18, recommending a "buy" rating for Olin Bio (688319.SH) at a latest price of 23.99 yuan, highlighting the company's growth potential in the vaccine market [2] Group 1: Market Expansion - The tetanus vaccine is experiencing continuous growth in demand, leading to an expanding market size [2] - The development of the golden staphylococcus vaccine is globally leading, indicating a broad future market prospect [2] Group 2: Clinical Progress - The company has received approval for Phase 1 clinical trials for its Helicobacter pylori vaccine in Australia, marking a significant milestone in its research and development efforts [2]